San Francisco, 20
September 2018: The global viral
inactivation market is
anticipated to reach USD 5.1 billion by 2025, growing at a CAGR of 12.5%,
according to a new report by Grand View Research, Inc. Rise in the number of
pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals,
growth of the life sciences industry, increase in government funding for novel
therapies, and drug development are some of the major factors contributing to
the growth.
Immense growth has been witnessed in the
pharmaceutical and biopharmaceutical industry with a steady rise in the number
of companies, drug launches, and new drug discoveries. With an increase in the
number of diseases worldwide, the need for new & improved drugs and
therapies has been witnessed on a global front. Increase in investment by top
players in research and development coupled with the need to find new therapies
for the treatment of diseases has contributed to immense growth of
pharmaceutical and biopharmaceutical companies, thereby accelerating growth.
Newer drugs are being developed by
companies to offer incremental health benefits. Changing lifestyle of people
across the globe and adoption of sedentary living habits are primary reasons
responsible for the increase in the number of chronic diseases that require
drugs and therapies for treatment. According to the FDA, in the year 2014, 41
novel drugs were approved and 45 in the consequent year. This has also been
contributing to growth.
Immense funding has been witnessed in the
pharmaceutical and biotechnology industries in the recent years. It has been
observed that private players are the major contributors for the development of
new drugs and therapies, however, there has been increasing government spending
on the research and development of new therapies. Increase in funding has also
resulted in growth in number of FDA approvals over the recent years. All these
factors have been contributing to the immense growth of the market.
Access
Research Report of Viral Inactivation
Market@ www.grandviewresearch.com/industry-analysis/viral-inactivation-market
Further Key Findings From the Study Suggest:
· Kits and reagents held the largest share
owing to increasing usage of consumables
· Vaccines and therapeutics held the largest
share, on the basis of application, and is expected to be the fastest growing
segment due to the increased demand for biologics
· The services segment is anticipated to grow
at the fastest rate due to increase in the number of pharmaceutical CROs
globally
· North America accounted for the largest
share owing to presence of dominant players and availability of sophisticated
infrastructure along with healthcare reforms to curb the incidence of chronic
diseases
· The Asia Pacific region is expected to
flourish during the forecast period owing to healthcare reforms and untapped
market opportunities in the pharmaceutical industry
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global viral inactivation market on the basis of product, application, end use,
and region:
Viral Inactivation Product Outlook
(Revenue, USD Million; 2014 - 2025)
·
Kits and Reagents
·
Systems
·
Services
Viral Inactivation Application Outlook
(Revenue, USD Million; 2014 - 2025)
·
Vaccines and Therapeutics
·
Stem Cell Products
·
Blood Tissue/Tissue Products
·
Blood and Blood Products
·
Cellular and Gene Therapy
Viral Inactivation End-use Outlook
(Revenue, USD Million; 2014 - 2025)
·
Pharmaceutical and Biopharmaceutical
Companies
·
CROs
·
Academic and Research Institutes
·
Others
Viral Inactivation Regional Outlook (Revenue,
USD Million; 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
o
France
o
Italy
o
Spain
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
o Saudi Arabia
Access
Press Release of Viral Inactivation Market@ www.grandviewresearch.com/press-release/global-viral-inactivation-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
